Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Filetti

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Psychophysiology|September 16, 2015
Latency as a region contrast: Measuring ERP latency differences with Dynamic Time WarpingA Zoumpoulaki, A Alsufyani, M Filetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplificationM Mazzotta, M Filetti, A Rossi, et al.
Breast (Edinburgh, Scotland)|March 25, 2025
Integration of translational research in phase III trials: A systematic review of breast cancer studies in a 5-year periodG Giannone, P Lombardi, M Filetti, et al.
ESMO Open|February 3, 2026
Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regressionG M Iannantuono, T Giovagnoli, L Mastrantoni, et al.
Leukemia|September 20, 2017
Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profileI Del Giudice, G M Rigolin, S Raponi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 2020
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burdenD Marinelli, M Mazzotta, S Scalera, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 9, 2019
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudesA Cortellini, A Leonetti, A Catino, et al.
ESMO Open|June 15, 2024
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)E G Pizzutilo, A G Agostara, S Oresti, et al.
ESMO Open|June 19, 2021
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078]G L Banna, A Cortellini, D L Cortinovis, et al.
ESMO Open|March 18, 2021
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancerG L Banna, A Cortellini, D L Cortinovis, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Psychophysiology|September 16, 2015
Latency as a region contrast: Measuring ERP latency differences with Dynamic Time WarpingA Zoumpoulaki, A Alsufyani, M Filetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 19, 2020
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplificationM Mazzotta, M Filetti, A Rossi, et al.
Breast (Edinburgh, Scotland)|March 25, 2025
Integration of translational research in phase III trials: A systematic review of breast cancer studies in a 5-year periodG Giannone, P Lombardi, M Filetti, et al.
ESMO Open|February 3, 2026
Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regressionG M Iannantuono, T Giovagnoli, L Mastrantoni, et al.
Leukemia|September 20, 2017
Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profileI Del Giudice, G M Rigolin, S Raponi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 1, 2020
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burdenD Marinelli, M Mazzotta, S Scalera, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 9, 2019
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudesA Cortellini, A Leonetti, A Catino, et al.
ESMO Open|June 15, 2024
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)E G Pizzutilo, A G Agostara, S Oresti, et al.
ESMO Open|June 19, 2021
Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078]G L Banna, A Cortellini, D L Cortinovis, et al.
ESMO Open|March 18, 2021
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancerG L Banna, A Cortellini, D L Cortinovis, et al.
Pageof 2